<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>162</id><JournalTitle>THALIDOMIDE AS ANTIEMETIC FOR CHEMOTHERAPYINDUCED NAUSEA AND VOMITING: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS</JournalTitle><Abstract>Aim of the study is to analyze the benefits of thalidomide for prevention of nausea and vomiting induced by cancer
chemotherapeutic agents. Electronic database search in PUBMED, Cochrane library, Google scholar was conducted using
search terms â€œthalidomideâ€ AND â€œvomitingâ€. Randomized or cross-over studies comparing antiemetic effects of thalidomide
vs other active treatment or placebo in cancer patients >18yrs on treatment with emetogenic cancer chemotherapeutic agents
were included for analysis. Complete control of vomiting was the primary outcome measure while the incidences of adverse
drug reactions and complete control of nausea, anorexia were the secondary outcome measures analyzed. Inverse variance
method and both random and fixed effect models were used in the analysis by RevMan 5.3 software. Total six eligible studies
were included in the analysis. Complete control of delayed vomiting was 1.22 times (RR: 1.2, 95% CI: 1.11, 1.30, N=881),
delayed nausea was 1.4 times (RR: 1.39, 95% CI: 1.19, 1.61, N=881) and anorexia was 1.65 times (RR: 1.65, 95% CI: 1.26,
2.16, N=183)higher in thalidomide group than in control group. Incidences of constipation (RR: 1.43, 95% CI: 1.21, 1.68,
N=1031), rashes/pruriris (RR: 9.03, 95% CI: 1.72, 47.45, N=130), peripheral neuropathy (RR: 1.67, 95% CI: 1.06, 2.64,
N=328) and sedation/somnolence (RR: 3.11, 95% CI : 1.90, 5.09, N=78) were higher in thalidomide group. Though
significant, benefit of thalidomide for delayed vomiting appears to be minimal and for delayed nausea, doubtful. The benefits
resemble the benefits ofNK1 receptor antagonists but its added benefits of anti-cancer actions may favor its use in cancer
patients.</Abstract><Email>dr.sharan83@yahoo.com</Email><articletype>Research</articletype><volume>10</volume><issue>1</issue><year>2020</year><keyword>Thalidomide,chemotherapy,CINV</keyword><AUTHORS>Sharanabasayyaswamy B Hiremath,Srinivas Lokikere Devendrappa</AUTHORS><afflication>Department of Pharmacology, Kodagu Institute of Medical Sciences, Madikeri, Karnataka,Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India</afflication></Article></Articles>